(NASDAQ: MDXG) Mimedx Group's forecast annual revenue growth rate of 1.87% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Mimedx Group's revenue in 2026 is $418,630,000.On average, 8 Wall Street analysts forecast MDXG's revenue for 2026 to be $52,288,009,943, with the lowest MDXG revenue forecast at $49,502,386,455, and the highest MDXG revenue forecast at $54,598,220,355. On average, 8 Wall Street analysts forecast MDXG's revenue for 2027 to be $59,096,816,579, with the lowest MDXG revenue forecast at $54,292,173,188, and the highest MDXG revenue forecast at $64,348,645,394.
In 2028, MDXG is forecast to generate $65,699,115,661 in revenue, with the lowest revenue forecast at $60,188,780,986 and the highest revenue forecast at $70,775,635,905.